Skip to content

menu

Reed Smith LLP logo
HomeAboutSubscribeTopicsOur ServicesContact
Search
Close

Health Industry Washington Watch

Updates by Reed Smith on U.S. legislative & regulatory developments affecting the health care industry

FDA Bioequivalence Recommendations

By Debra A. McCurdy on 8 July 2008
Print:
Email this postTweet this postLike this postShare this post on LinkedIn

The FDA has released final guidance to industry on individual product bioequivalence recommendations.

Posted in Food & Drug Administration Regulations, Other FDA Developments
Tags: Food & Drug Administration Developments, Other FDA Developments
Related Posts
FDA codifies requirements for the medical device De Novo classification process
October 14, 2021
FDA clarifies evidence and knowledge requirements in intended use final rule
August 26, 2021
Marketers Beware: As COVID-19 cases increase, FDA, FTC increase efforts to crack down on fraudulent and deceptive marketing and sales of purported ‘Virus Cures’
December 1, 2020

Subscribe to Health Industry Washington Watch

Updates direct to your inbox
Subscribe by Email

Links & Resources

Key Regulatory Sites

  • CMS
  • FDA
  • Federal Register
  • HHS
  • HHS OIG

Key Legislative Sites

  • Congressional Record
  • House Energy and Commerce Committee
  • House Ways and Means Committee
  • Senate Finance Committee
  • Thomas (Library of Congress)

Health Industry Washington Watch

View Our Network of Blogs
Published by
Reed Smith LLP logo
RSS Twitter Facebook LinkedIn youtube
Privacy PolicyDisclaimer

About Our Firm

Reed Smith represents many of the world’s leading companies in complex litigation and other high-stakes disputes, cross-border and other strategic transactions, and crucial regulatory matters.

Read More...

Topics

Archives

Copyright © 2023, Reed Smith LLP. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo